Hematologic malignancies magnify the effect of body mass index on insulin resistance in cancer survivors.

ABSTRACT: Cancer survivors are at increased risk of type 2 diabetes, which usually develops from obesity and insulin resistance. Whether diabetes susceptibility is due to shared risk factors for cancer and insulin resistance or directly related to cancer and its treatment is unknown. We investigated effect modification between malignancy and body mass index (BMI) as determinants of insulin sensitivity in patients with hematologic malignancies and controls without cancer. In a cross-sectional study of 43 individuals without diabetes (20 patients with treated hematologic malignancies; 23 controls without malignancies), we measured insulin-stimulated whole-body glucose use (M) by hyperinsulinemic euglycemic clamp. Insulin sensitivity index (ISI) was calculated by dividing M over steady-state plasma ins

SUBMITTER: Sahinoz M 

PROVIDER: S-EPMC9006273 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature